104 related articles for article (PubMed ID: 7678072)
1. Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein.
Arceci RJ; Stieglitz K; Bras J; Schinkel A; Baas F; Croop J
Cancer Res; 1993 Jan; 53(2):310-7. PubMed ID: 7678072
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.
Schinkel AH; Roelofs EM; Borst P
Cancer Res; 1991 May; 51(10):2628-35. PubMed ID: 1673638
[TBL] [Abstract][Full Text] [Related]
3. High-affinity monoclonal antibodies against P-glycoprotein.
Shi T; Wrin J; Reeder J; Liu D; Ring DB
Clin Immunol Immunopathol; 1995 Jul; 76(1 Pt 1):44-51. PubMed ID: 7541735
[TBL] [Abstract][Full Text] [Related]
4. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
5. Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein.
Hamada H; Miura K; Ariyoshi K; Heike Y; Sato S; Kameyama K; Kurosawa Y; Tsuruo T
Cancer Res; 1990 Jun; 50(11):3167-71. PubMed ID: 1970754
[TBL] [Abstract][Full Text] [Related]
6. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase.
Rao VV; Anthony DC; Piwnica-Worms D
Cancer Res; 1994 Mar; 54(6):1536-41. PubMed ID: 7511043
[TBL] [Abstract][Full Text] [Related]
7. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
8. Expression of P-glycoprotein in normal muscle cells and myogenic tumors.
Garberoglio C; Dudas M; Casper ES; Bertino J; Cordon-Cardo C
Arch Pathol Lab Med; 1992 Oct; 116(10):1055-61. PubMed ID: 1384456
[TBL] [Abstract][Full Text] [Related]
9. Antigens associated with multidrug resistance in H69AR, a small cell lung cancer cell line.
Mirski SE; Cole SP
Cancer Res; 1989 Oct; 49(20):5719-24. PubMed ID: 2571409
[TBL] [Abstract][Full Text] [Related]
10. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
11. Detection of soluble P-glycoprotein in culture media and extracellular fluids.
Chu TM; Lin TH; Kawinski E
Biochem Biophys Res Commun; 1994 Aug; 203(1):506-12. PubMed ID: 7915520
[TBL] [Abstract][Full Text] [Related]
12. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Rao VV; Chiu ML; Kronauge JF; Piwnica-Worms D
J Nucl Med; 1994 Mar; 35(3):510-5. PubMed ID: 7906729
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.
Sugawara I; Kataoka I; Morishita Y; Hamada H; Tsuruo T; Itoyama S; Mori S
Cancer Res; 1988 Apr; 48(7):1926-9. PubMed ID: 2894894
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
15. Epitope mapping of the monoclonal antibody MM12.10 to external MDR1 P-glycoprotein domain by synthetic peptide scanning and phage display technologies.
Romagnoli G; Poloni F; Flego M; Moretti F; Di Modugno F; Chersi A; Falasca G; Signoretti C; Castagna M; Cianfriglia M
Biol Chem; 1999 May; 380(5):553-9. PubMed ID: 10384961
[TBL] [Abstract][Full Text] [Related]
16. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
18. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
